Bone Biologics Valuation
| BBLG Stock | USD 0.88 0.06 7.32% |
Today, the firm appears to be undervalued. Bone Biologics Corp shows a prevailing Real Value of $10.08 per share. The current price of the firm is $0.88. Our model approximates the value of Bone Biologics Corp from analyzing the firm fundamentals such as Current Valuation of (446.62 K), shares owned by insiders of 2.12 %, and Return On Equity of -1.29 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Bone Biologics' valuation include:
Undervalued
Today
Please note that Bone Biologics' price fluctuation is slightly risky at this time. Calculation of the real value of Bone Biologics Corp is based on 3 months time horizon. Increasing Bone Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Bone stock is determined by what a typical buyer is willing to pay for full or partial control of Bone Biologics Corp. Since Bone Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bone Stock. However, Bone Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.88 | Real 10.08 | Target 37.75 | Hype 0.88 | Naive 0.96 |
The real value of Bone Stock, also known as its intrinsic value, is the underlying worth of Bone Biologics Corp Company, which is reflected in its stock price. It is based on Bone Biologics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Bone Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Bone Biologics Corp helps investors to forecast how Bone stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bone Biologics more accurately as focusing exclusively on Bone Biologics' fundamentals will not take into account other important factors: When choosing an evaluation method for Bone Biologics Corp, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Bone Biologics Cash |
|
Bone Valuation Drivers Correlation
Many accounts on the financial statements of Bone Biologics Corp are highly interrelated and sometimes correlated. Consequently, when conducting Bone's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Bone
Click cells to compare fundamentals
Bone Valuation Trend
Comparing Bone Biologics' enterprise value against its market capitalization is a good way to estimate the value of Bone Biologics Corp uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Bone Biologics Total Value Analysis
Bone Biologics Corp is currently expected to have valuation of (446.62 K) with market capitalization of 2.88 M, debt of 377.71 K, and cash on hands of 5.45 M. The negative valuation of Bone Biologics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Bone Biologics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(446.62 K) | 2.88 M | 377.71 K | 5.45 M |
Bone Biologics Asset Utilization
One of the ways to look at asset utilization of Bone is to check how much profit was generated for every dollar of assets it reports. Bone Biologics Corp shows a negative utilization of assets of -0.69 percent, losing $0.00694 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Bone Biologics Corp shows how discouraging it operates for each dollar spent on its assets.Bone Biologics Ownership Allocation
Almost 95.74 percent of Bone Biologics outstanding shares are held by general public with 2.12 (percent) owned by insiders and only 2.14 % by other corporate entities.Bone Biologics Profitability Analysis
Net Loss for the year was (4.11 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Bone Biologics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Bone Biologics and how it compares across the competition.
About Bone Biologics Valuation
The stock valuation mechanism determines Bone Biologics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Bone Biologics. We calculate exposure to Bone Biologics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bone Biologics's related companies.Bone Biologics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Bone Biologics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.5 M |
Bone Biologics Current Valuation Indicators
Valuation refers to the process of determining the present value of Bone Biologics Corp and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Bone we look at many different elements of the entity such as Bone's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Bone Biologics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Bone Biologics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Bone Biologics' worth.Complementary Tools for Bone Stock analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Transaction History View history of all your transactions and understand their impact on performance |